Application of ITGB4 / BNIP3 signal axis blocker in preparation of pancreatic cancer immunotherapy drug
The ITGB4/BNIP3 signaling axis blocker inhibits autophagy and MHC-I expression of pancreatic cancer cells, combined with PD-1a treatment, solves the problem of immune escape of pancreatic cancer, significantly improves the treatment effect, enhances the sensitivity of immunotherapy and Effect.
Patent Information
- Application Number
- CN202411130834.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The traditional treatment methods of pancreatic cancer are not effective, and the mechanism of cellular immune escape in immunotherapy is unknown, especially the mechanism of ITGB4 and BNIP3 in pancreatic cancer cells has not been studied in depth, affecting the effect of immunotherapy.
Develop ITGB4/BNIP3 signaling axis blocker, inhibits autophagy and MHC-I expression of pancreatic cancer cells by blocking ITGB4 and BNIP3 signaling axis, and combines PD-1a immunotherapy to enhance CD8+ T cell infiltration and improve pancreatic cancer Immunotherapy effects.
Effectively inhibit the immune escape of pancreatic cancer cells, improve the effect of PD-1a treatment, significantly reduce tumor growth rate and tumor weight, and enhance the sensitivity of immunotherapy.
Smart Images

Figure CN118903431A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to application of an ITGB4 / BNIP3 signal axis blocker in the preparation of a pancreatic cancer immunotherapy drug. Background Art
[0002] Pancreatic cancer presents many characteristics such as high malignancy and poor clinical prognosis. Traditional treatment methods such as surgery, chemotherapy and radiotherapy have not achieved the expected results in the treatment of such patients. It is necessary to find appropriate treatment methods to improve the survival rate of pancreatic cancer and improve the prognosis of patients. Immunotherapy, as a new treatment strategy, specifically identifies pathogens and cancer cells, induces the immune system to kill pancreatic cancer cells, and reduces the toxic side effects caused by traditional treatment methods. However, there are certain problems in the process of immunotherapy. For example, the use of immune checkpoint inhibitors alone is ineffective for pancreatic cancer. This may be because pancreatic cancer has a low immune mutation load and new epitope load (cancer cells have low immunogenicity and produce few immunogenic antigens), as well as few or no endogenous tumor infiltrating lymphocytes. Therefore, we need to further study the immune escape mechanism of pancreatic cancer and develop new immunotherapy drugs targeting the specificity of pancreatic cancer.
[0003] ITGB4 (Integrin Beta-4) is a gene located on chromosome 17. The protein encoded by this gene is the integrin β4 subunit, which is involved in regulating the proliferation, apoptosis, invasion and metastasis of cancer cells. According to research reports, ITGB4 may be involved in the autophagy of pancreatic cancer cells. In tumor immunotherapy, cell autophagy can bidirectionally regulate the body's immune system to affect the effect of immunotherapy. Therefore, exploring the mechanism of action of ITGB4 and autophagy of pancreatic cancer cells will have far-reaching significance and can also provide new ideas for immunotherapy of pancreatic cancer. BNIP3 belongs to the BH3-only subfamily of the Bcl-2 protein superfamily. It can bind to the protein encoded by the adenovirus transcription gene E1B or the Bcl-2 protein, and is a functional protein that can regulate cell apoptosis and autophagy. So, whether ITGB4 and BNIP3 are related and have an effect, whether they can jointly regulate the autophagy of pancreatic cancer cells and perform immune regulation, is still unknown. Therefore, in-depth research on the mechanism of action of ITGB4 and BNIP3 in pancreatic cancer cells and whether they can participate in the immune regulation of pancreatic cancer cells are awaited. Summary of the invention
[0004] Based on the above problems, the present invention deeply studies the action mechanism of ITGB4 and BNIP3 in pancreatic cancer cells, and proposes an application of an ITGB4 / BNIP3 signaling axis blocker in the preparation of pancreatic cancer immunotherapy drugs. This application provides a new idea for the development of blockers that target the ITGB4 / BNIP3 signaling axis for the preparation of pancreatic cancer immunotherapy drugs, and provides a scientific basis for the application of combined PD-1a immunotherapy drugs in the treatment of pancreatic cancer.
[0005] To achieve the above-mentioned purpose, the present invention provides the following technical solutions:
[0006] Use of an ITGB4 expression blocker in the preparation of a pancreatic cancer immunotherapy drug.
[0007] Preferably, the ITGB4 expression blocker is used for at least one of the agents that inhibit the expression of LC3Ⅰ, LC3Ⅱ, Beclin1 and promote the expression of MHC-Ⅰ.
[0008] Preferably, the ITGB4 and BNIP3 have a strong binding relationship, and the ITGB4 and BNIP3 form an ITGB4 / BNIP3 signaling axis, which activates the autophagy function of pancreatic cancer cells, degrades MHC-Ⅰ expression, and promotes the occurrence of pancreatic cancer cell immune escape.
[0009] Application of an ITGB4 / BNIP3 signaling axis blocker in the preparation of pancreatic cancer immunotherapy drugs.
[0010] Preferably, the ITGB4 / BNIP3 signaling axis blocker is used as at least one of the agents that inhibit the expression of autophagy-related genes LC3Ⅰ, LC3Ⅱ, Beclin1, and promote the expression of MHC-Ⅰ.
[0011] Application of an ITGB4 / BNIP3 signaling axis blocker combined with an immunotherapy drug in the treatment of pancreatic cancer.
[0012] Preferably, the application thereof knocks down ITGB4 expression, combines with PD-1a treatment, and reduces the expression levels of autophagy-related genes and proteins, CD8 + T cell immune infiltration increased, tumor growth rate and tumor weight were inhibited, and the therapeutic effect of PD-1a was further promoted.
[0013] A drug or a drug composition for improving the therapeutic sensitivity of pancreatic cancer immune checkpoint inhibitors, characterized in that the drug or the drug composition contains an effective pharmaceutical active substance that inhibits ITGB4 expression.
[0014] Preferably, the drug or pharmaceutical composition thereof knocks down ITGB4 expression, and combined with PD-1a treatment, the expression levels of autophagy-related genes and proteins decrease, CD8+ T cell immune infiltration increased, tumor growth rate and tumor weight were inhibited, and the therapeutic effect of PD-1a was further promoted.
[0015] Compared with the prior art, the present invention has the following beneficial effects:
[0016] (1) The present invention transfected oeITGB4 and shBNIP3 into pancreatic cancer cell lines, and detected the expression levels of BNIP3, MHC-I and autophagy-related proteins by WB. It was found that ITGB4 and BNIP3 can together regulate the autophagy of pancreatic cancer cells to achieve the immune escape of pancreatic cancer cells, and can be used as a new immunotherapy drug for blocking ITGB4 and BNIP3 overexpression pancreatic cancer.
[0017] (2) The present invention uses Co-IP experiments, flow cytometry and confocal microscopy to observe and find that ITGB4 and BNIP3 promote pancreatic cancer cell autophagy by binding to each other, reduce cell surface MHC-I expression, and thus achieve immune escape. Therefore, the research results provide theoretical support for the application of reagents that target and block the ITGB4 / BNIP3 signaling axis in the preparation of pancreatic cancer immunotherapy drugs.
[0018] (3) The present invention constructs an ITGB4-deficient pancreatic cancer mouse model by silencing ITGB4 and inhibiting the ITGB4 / BNIP3 signaling axis. After receiving PD-1a treatment, it is found that the mouse model has a better immunotherapy effect than the conventional PD-1a immunotherapy for pancreatic cancer mice. This provides a new direction for the development of immunotherapy drugs for pancreatic cancer using ITGB4 / BNIP3 signaling axis inhibitors combined with PD-1a. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 WB was used to detect the protein expression levels of ITGB4 and autophagy-related proteins (LC3I, LC3 II, Beclin1) in PANC-1 and KP-4 cell lines after transfection of shITGB4.
[0020] Figure 2 PANC-1 and KP-4 were treated with shNC+PBS, shITGB4+PBS, and shITGB4+EBSS, respectively, and the expression levels of ITGB4, LC3 II / I, Beclin1, and MHC-I proteins were detected by WB.
[0021] Figure 3 PANC-1 and KP-4 were treated with oeNC+shNC, oeITGB4+shNC, and oeITGB4+shBNIP3, respectively. Figure 3 A is WB detection of BNIP3, LC3 II / I, Beclin1 and MHC-I protein expression levels. Figure 3 B: The interaction between ITGB4 and BNIP3 was verified by Co-IP in 293T cells.
[0022] Figure 4 AC is the expression level of MHC-I protein on the cell membrane in each group detected by flow cytometry, * indicates P < 0.05.
[0023] Figure 5 The co-localization relationship between MHC-I (red) and autophagosomes (LC3, green) in cells was observed under a confocal microscope.
[0024] Figure 6 The effect of ITGB4 / BNIP3 on the efficacy of PD-1 monoclonal antibody immunotherapy was verified in a homologous transplanted tumor mouse model: Figure 6 Statistical analysis of tumor volume and weight in groups AB; Figure 6 C is the mRNA expression levels of ITGB4 and BNIP3 in tumor tissues of each group detected by qRT-PCR; Figure 6 D is the protein expression level of autophagy-related proteins in tumor tissues of each group detected by WB; Figure 6 E is the expression level of MHC-I on the cell surface in tumor tissue detected by flow cytometry; Figure 6 FFlow cytometry was used to detect the expression of CD8 + CD3 + Cell ratio. * indicates P < 0.05, ns indicates no significant difference. DETAILED DESCRIPTION
[0025] The present invention is described in detail below with reference to the embodiments.
[0026] Example 1: ITGB4 induces autophagy in pancreatic cancer cells
[0027] Experimental methods: The constructed shNC, shITGB4 pLKO.1-puro lentiviral plasmids and packaging plasmids psPAX2 and pMD2.G were co-transfected into HEK293FT cells at a certain ratio to produce lentivirus. After 48 hours of transfection, the viral supernatant was collected, filtered with a 0.45μM filter, and infected with Polybrene PANC-1 and KP-4 cells, and cells stably expressing shRNA were selected with puromycin. After obtaining PANC-1 and KP-4 cells stably expressing shITGB4, the protein expression of ITGB4 and autophagy-related proteins (LC3 II / I, Beclin1) in PANC-1 and KP-4 cells was observed by WB experiment.
[0028] Experimental results: WB results are as follows Figure 1As shown in the figure, ITGB4, LC3 II / I and Beclin1 are highly expressed in PANC-1 and KP-4; after knocking down ITGB4, the expression levels of ITGB4, LC3 II / I and Beclin1 were reduced, which shows that ITGB4 can induce autophagy in pancreatic cancer cells.
[0029] Example 2: ITGB4 reduces the expression of MHC-I on the surface of cancer cells through autophagy
[0030] Experimental method: The experimental steps of obtaining PANC-1 and KP-4 cells stably expressing shITGB4 were as in Example 1, and then the experimental groups shNC+PBS group (shITGB4 gene was not transfected), shITGB4+PBS group (shITGB4 gene was transfected), and shITGB4+EBSS group (shITGB4 gene was transfected and autophagy inducer EBSS was added) were set up, and the expression of ITGB4, autophagy-related proteins (LC3 II / I) and MHC-I proteins in PANC-1 and KP-4 cells was detected by WB.
[0031] Experimental results: WB results are as follows Figure 2 As shown in the figure, in PANC-1 and KP-4 cells, compared with the shNC+PBS group, the expression of ITGB4 and autophagy-related proteins in the shITGB4+PBS group was reduced, and the expression of MHC-I was increased. However, after knocking down ITGB4 and adding the autophagy inducer EBSS, cell autophagy returned to its previous level, and the expression of MHC-I protein decreased. The experimental results show that ITGB4 can reduce MHC-I on the cell surface by inducing autophagy in pancreatic cancer cells.
[0032] Example 3: ITGB4 activates cell autophagy and degrades MHC-I by binding to BNIP3
[0033] Experimental methods: In this experiment, pancreatic cancer cell lines (PANC-1 and KP-4) were transfected with oeITGB4 and shBNIP3. The experimental groups were divided into oeNC+shNC group (no transfection of oeITGB4 and shBNIP3 genes), oeITGB4+shNC group (only transfection of oeITGB4 gene), and oeITGB4+shBNIP3 group (transfection of oeITGB4 and shBNIP3 genes). The expression levels of BNIP3, MHC-I and autophagy-related proteins in each group were detected by WB, the interaction between ITGB4 and BNIP3 was observed by Co-IP experiment, the expression of MHC-Ⅰ on the cell surface was observed by flow cytometry, and the co-localization relationship between MHC-I and autophagosome in cells was observed under confocal microscopy.
[0034] Experimental results: The results are as follows Figure 3As shown in A, compared with the oeNC+shNC group, the expression levels of LC3 II / I and Beclin1 proteins in the oeITGB4+shNC group increased, and cellular autophagy further increased. At the same time, the expression level of MHC-I protein decreased, indicating that overexpression of ITGB4 can regulate the increase in the expression of autophagy genes LC3 II / I and Beclin1, and reduce the expression of MHC-Ⅰ by increasing cellular autophagy, thereby helping pancreatic cancer cells to escape immune function. However, when the cells were transfected with oeITGB4 and shBNIP3 at the same time, compared with the oeITGB4+shNC group, the expression level of BNIP3 protein decreased, and the expression level of autophagy-related proteins also decreased. At this time, autophagy was inhibited and the expression level of MHC-I increased. The results showed that ITGB and BNIP3 may jointly regulate cellular autophagy. From the analysis of protein expression levels, when ITGB4 was overexpressed, there was no significant difference in the expression level of BNIP3, indicating that ITGB4 did not directly affect the expression level of BNIP3. Further verification was performed through Co-IP experiments. According to Figure 3 As shown in B, when ITGB4 is pulled down, another protein bound to it can be detected, indicating that ITGB4 and BNIP3 promote the occurrence of cellular autophagy through mutual binding between the two.
[0035] In addition, to further verify that ITGB4 and BNIP3 promote the occurrence of cellular autophagy through their mutual binding, flow cytometry results were as follows Figure 4 As shown in AC, the expression level of MHC-I on the surface of pancreatic cancer cells decreased in the ITGB4 overexpression group under different treatments, and increased in the group co-transfected with oeITGB4 and shBNIP3, which is consistent with Figure 3 The WB experimental results in A are consistent. Next, the present invention observed the co-localization relationship between MHC-I and autophagosomes in cells under a confocal microscope. Figure 5 It can be seen that when cells were transfected with oeITGB4 and shBNIP3 at the same time, the co-localization degree of MHC-I and LC3-labeled autophagosomes decreased, which is consistent with the above-mentioned trend of increased MHC-I expression. In summary, in pancreatic cancer cells, the ITGB4 / BNIP3 axis can activate cell autophagy and degrade MHC-I, hindering the presentation of tumor antigens and causing immune escape.
[0036] Example 4: Verification of the effect of ITGB4 / BNIP3 signaling axis inhibitors on the efficacy of PD-1a immunotherapy using a homologous transplant mouse model
[0037] Experimental method: In order to test whether inhibition of ITGB4 / BNIP3 signaling pathway would make pancreatic cancer sensitive to immune checkpoint inhibitors, the present invention transplanted Panc02 cells transfected with shNC and shITGB4 into the abdomen of C57BL / 6 mice, and PD-1a was injected into the tail of one group of shNC and shITGB4. At the end of the experiment, the mice were killed, and the changes in tumor size and weight were observed. The mRNA levels of ITGB4 and BNIP3 and the protein expression levels of autophagy-related proteins were detected by qRT-PCR and WB, respectively. The cell surface MHC-I expression level and immune cell activity in the tumor tissue of each group were detected by flow cytometry.
[0038] Experimental results: The research results are as follows Figure 6 As shown in AB, after receiving PD-1a treatment, the tumor growth rate and tumor weight were inhibited, and after knocking down ITGB4 expression, the PD-1a treatment effect was more obvious; qRT-PCR and WB results are shown in Figure 6 CD, compared with the shNC+PD-1a group, the mRNA level of ITGB4 and the expression of autophagy-related proteins in the shITGB4+PD-1a group were reduced, and there was no significant difference in the mRNA level of BNIP3; the results of flow cytometry were as follows Figure 6 As shown in E, the expression of cell surface MHC-I in the shITGB4+PD-1a group was significantly higher than that in the shNC+PBS and shNC+PD-1a groups. Therefore, in vivo experiments also proved that ITGB4 / BNIP3 can promote autophagy degradation of MHC-I in pancreatic cancer cells, and autophagy inhibition can restore MHC-I on the cell membrane surface, thereby making PD-1a have a significant therapeutic effect. In order to further explore whether ITGB4 / BNIP3 activation of autophagy degradation of MHC-I will affect the anti-tumor immunity of pancreatic cancer cells, the present invention used flow cytometry to detect the activity of immune cells. The statistical results are shown in Figure 6 As shown in F, compared with the shNC+PD-1a group, the CD3 + / CD8 + The expression was significantly increased, showing a large number of CD8 + In summary, the present invention found through in vivo experiments that ITGB4 / BNIP3 activated autophagy in pancreatic cancer cells, resulting in a decrease in MHC-I expression. When autophagy was inhibited, pancreatic cancer cells were more sensitive to PD-1a, and the immunotherapy effect was more significant.
Claims
1. Application of an ITGB4 expression blocker in the preparation of pancreatic cancer immunotherapy drugs.
2. The use according to claim 1, It is characterized in that The ITGB4 expression blocker is used for at least one of the reagents that inhibit the expression of LC3Ⅰ, LC3Ⅱ, Beclin1 and promote the expression of MHC-1.
3. The use according to claim 1, It is characterized in that The ITGB4 and BNIP3 have a strong binding relationship, and the ITGB4 and BNIP3 form an ITGB4 / BNIP3 signaling axis, which activates the autophagy function of pancreatic cancer cells, degrades MHC-Ⅰ expression, and promotes the occurrence of pancreatic cancer cell immune escape.
4. Application of an ITGB4 / BNIP3 signaling axis blocker in the preparation of pancreatic cancer immunotherapy drugs.
5. The use according to claim 4, It is characterized in that The ITGB4 / BNIP3 signal axis blocker is used for at least one of the reagents that inhibit the expression of autophagy-related genes LC3Ⅰ, LC3Ⅱ, Beclin1, and promote the expression of MHC-Ⅰ.
6. Application of an ITGB4 / BNIP3 signaling axis blocker combined with an immunotherapy drug in the treatment of pancreatic cancer.
7. The use according to claim 7, It is characterized in that The application knocks down ITGB4 expression and combines with PD-1a treatment to reduce the expression levels of autophagy-related genes and proteins, and CD8 + T cell immune infiltration increased, tumor growth rate and tumor weight were inhibited, and the therapeutic effect of PD-1a was further promoted.
8. A drug or a drug composition for improving the sensitivity of pancreatic cancer to immune checkpoint inhibitor therapy, It is characterized in that The medicine or the medicine composition contains effective pharmaceutical active substances that inhibit the expression of ITGB4.
9. The drug or pharmaceutical composition according to claim 8, It is characterized in that The drug or drug composition knocks down ITGB4 expression and combines with PD-1a treatment to reduce the expression levels of autophagy-related genes and proteins, CD8 + T cell immune infiltration increased, tumor growth rate and tumor weight were inhibited, and the therapeutic effect of PD-1a was further promoted.
